



1145 Corporate Lake Drive, Suite 100
St. Louis, Missouri 63132, USA
Tel 314.993.0003
Toll Free 800.878.4267
Fax 314.993.0075

For more information: David Murphy
Senior Director of Marketing and Communications
CMS
Tel: (314) 812-4320
dmurphy@cmsrtp.com
9991-950-123A

**CMS Collaborates with Mitsubishi Electric for Particle Therapy
*XiO Treatment Planning Solution to Support New Mitsubishi Delivery System and New
Particle Dose Engine Developed by NIRS***

St Louis, MO (October 28, 2007) – CMS, Inc. (CMS) the worldwide market leader in radiation treatment planning and workflow management, announced the signing of a development agreement with Mitsubishi Electric Corporation (Melco) of Japan to provide treatment planning support for Melco's new particle therapy systems for cancer care.

The partnership builds upon the existing clinical collaboration and commercial partnership between CMS and Melco in the area of particle therapy and leverages CMS's product capabilities and market leadership position in particle therapy planning. Pursuant to the agreement, CMS will enhance the functionality of its XiO treatment planning system to ensure XiO supports the specific planning requirements of Melco's new particle therapy system being developed for the National Institute of Radiological Science (NIRS) in Japan. The development agreement also includes connectivity support within XiO for a direct interface to the new external particle dose calculation engine being developed by the NIRS.

CMS' XiO is a comprehensive treatment planning system that combines the latest tools and the most robust dose calculation algorithms, allowing users to generate treatment plans quickly and accurately to optimize the delivery of radiation therapy. XiO's integrated planning capabilities support a range of treatment modalities, including 3-D, MLC-based IMRT (both sliding window and step-and-shoot), solid compensator-based IMRT, brachytherapy, and proton therapy. XiO leverages the speed and performance capabilities of the Linux operating system and the processing power of dual Intel processors to deliver superior 3-D image rendering, real-time image manipulation, and rapid calculation times.

XiO supports proton as well as conventional photon and electron treatment planning. Developed over a decade ago in collaboration with leading researchers and clinicians at the Massachusetts General Hospital, XiO's proton planning capabilities are utilized at leading proton treatment sites and research institutions throughout the U.S., Europe and Japan. Currently, CMS has more proton facilities using its planning solutions than any other commercial vendor, and its systems are used in conjunction with IBA, Melco, and Varian/Accel delivery systems.

"We are delighted to extend our partnership with Melco and the NIRS to provide carbon ion treatment planning solutions," said Andrew C. Cowen, President and CEO of CMS. "We have enjoyed a strong relationship with Mitsubishi and the NIRS in the area of particle therapy and look forward to applying our capabilities and expertise to this new project."

CMS is a worldwide leader in the development and support of radiation treatment planning and workflow management solutions. With treatment planning systems installed in more than 1,500 sites worldwide, CMS is a global resource to radiation oncology community. A privately held corporation, CMS employs over 290 professionals in its headquarters located in St. Louis, MO and regional offices in Tampa, Florida; Freiburg, Germany; Tokyo, Japan; Sydney, Australia; and Shanghai, China.

Forward-Looking Statements

Statements contained in this release, which are not historical facts, may be considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and the current economic environment.

We caution the reader that such forward-looking statements are not guarantees of future performance. Unknown risk, uncertainties as well as other uncontrollable or unknown factors could cause actual results to materially differ from the results, performance or expectations expressed or implied by such forward-looking statements.